Literature DB >> 23358465

Effect of Trastuzumab on Notch-1 Signaling Pathway in Breast Cancer SK-BR3 Cells.

Ming Han1, Hua-Yu Deng, Rong Jiang.   

Abstract

OBJECTIVE: To investigate the effects and mechanisms of trastuzumab on Notch-1 pathway in breast cancer cells, recognizing the significance of Notch-1 signaling pathway in trastuzumab resistance.
METHODS: Immunocytochemistry staining and Western blotting were employed to justify the expression of Notch-1 protein in HER2-overexpressing SK-BR3 cells and HER2-non-overexpressing breast cancer MDA-MB-231 cells. Western blotting and reverse transcription PCR (RT-PCR) were used to detect the activated Notch-1 and Notch-1 target gene HES-1 mRNA expression after SK-BR3 cells were treated with trastuzumab. Double immunofluorescence staining and co-immunoprecipitation were used to analyze the relationship of Notch-1 and HER2 proteins.
RESULTS: The level of Notch-1 nuclear localization and activated Notch-1 proteins in HER2-overexpressing cells were significantly lower than in HER2-non-overexpressing cells (P<0.01), and the expressions of activated Notch-1 and HES-1 mRNA were obviously increased after trastuzumab treatment (P<0.05), but HER2 expression did not change significantly for trastuzumab treating (P>0.05). Moreover, Notch-1 was discovered to co-localize and interact with HER2 in SK-BR3 cells.
CONCLUSION: Overexpression of HER2 decreased Notch-1 activity by the formation of a HER2-Notch1 complex, and trastuzumab can restore the activity of Notch-1 signaling pathway, which could be associated with cell resistance to trastuzumab.

Entities:  

Keywords:  Breast cancer; HER2; Notch-1; Trastuzumab

Year:  2012        PMID: 23358465      PMCID: PMC3555277          DOI: 10.1007/s11670-012-0213-9

Source DB:  PubMed          Journal:  Chin J Cancer Res        ISSN: 1000-9604            Impact factor:   5.087


  33 in total

1.  Mechanistic and signaling analysis of Muc4-ErbB2 signaling module: new insights into the mechanism of ligand-independent ErbB2 activity.

Authors:  Goldi A Kozloski; Coralie A Carothers Carraway; Kermit L Carraway
Journal:  J Cell Physiol       Date:  2010-09       Impact factor: 6.384

2.  Notch-1 and notch-4 receptors as prognostic markers in breast cancer.

Authors:  Katharine Yao; Paola Rizzo; Prabha Rajan; Kathy Albain; Karen Rychlik; Sneha Shah; Lucio Miele
Journal:  Int J Surg Pathol       Date:  2010-05-05       Impact factor: 1.271

Review 3.  Role of Notch and its oncogenic signaling crosstalk in breast cancer.

Authors:  Shanchun Guo; Mingli Liu; Ruben R Gonzalez-Perez
Journal:  Biochim Biophys Acta       Date:  2010-12-28

4.  Pro-apoptotic and anti-proliferative effects of mitofusin-2 via Bax signaling in hepatocellular carcinoma cells.

Authors:  Weilin Wang; Jianju Lu; Feng Zhu; Jianfeng Wei; Changku Jia; Yuanbiao Zhang; Lin Zhou; Haiyang Xie; Shusen Zheng
Journal:  Med Oncol       Date:  2010-12-29       Impact factor: 3.064

5.  Notch induces cyclin-D1-dependent proliferation during a specific temporal window of neural differentiation in ES cells.

Authors:  Debashish Das; Fredrik Lanner; Heather Main; Emma R Andersson; Olaf Bergmann; Cecilia Sahlgren; Nina Heldring; Ola Hermanson; Emil M Hansson; Urban Lendahl
Journal:  Dev Biol       Date:  2010-09-29       Impact factor: 3.582

6.  Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2.

Authors:  Roberto Gennari; Sylvie Menard; Francesco Fagnoni; Luisa Ponchio; Mario Scelsi; Elda Tagliabue; Fabio Castiglioni; Laura Villani; Cesare Magalotti; Nadia Gibelli; Barbara Oliviero; Bettina Ballardini; Gianantonio Da Prada; Alberto Zambelli; Alberto Costa
Journal:  Clin Cancer Res       Date:  2004-09-01       Impact factor: 12.531

Review 7.  Notch signaling and its role in breast cancer.

Authors:  Fangting Wu; Alan Stutzman; Yin-Yuan Mo
Journal:  Front Biosci       Date:  2007-05-01

Review 8.  ErbB receptors and signaling pathways in cancer.

Authors:  Nancy E Hynes; Gwen MacDonald
Journal:  Curr Opin Cell Biol       Date:  2009-02-07       Impact factor: 8.382

9.  TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms.

Authors:  L W Ellisen; J Bird; D C West; A L Soreng; T C Reynolds; S D Smith; J Sklar
Journal:  Cell       Date:  1991-08-23       Impact factor: 41.582

10.  Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer.

Authors:  Rupert Bartsch; Catharina De Vries; Ursula Pluschnig; Peter Dubsky; Zsuzsanna Bago-Horvath; Simon P Gampenrieder; Margaretha Rudas; Robert M Mader; Andrea Rottenfusser; Christoph Wiltschke; Michael Gnant; Christoph C Zielinski; Guenther G Steger
Journal:  BMC Cancer       Date:  2009-10-17       Impact factor: 4.430

View more
  6 in total

Review 1.  The Therapeutic Challenge of Targeting HER2 in Endometrial Cancer.

Authors:  Elisabeth J Diver; Rosemary Foster; Bo R Rueda; Whitfield B Growdon
Journal:  Oncologist       Date:  2015-06-22

2.  Differential peripheral blood gene expression profile based on Her2 expression on primary tumors of breast cancer patients.

Authors:  Oana Tudoran; Oana Virtic; Loredana Balacescu; Laura Pop; Flaviu Dragla; Alexandru Eniu; Bogdan Fetica; Ovidiu Balacescu; Ioana Berindan-Neagoe
Journal:  PLoS One       Date:  2014-07-28       Impact factor: 3.240

3.  miR-217 and CAGE form feedback loop and regulates the response to anti-cancer drugs through EGFR and HER2.

Authors:  Youngmi Kim; Hyuna Kim; Deokbum Park; Minho Han; Hansoo Lee; Yun Sil Lee; Jongseon Choe; Young Myeong Kim; Dooil Jeoung
Journal:  Oncotarget       Date:  2016-03-01

4.  Combination therapy of RY10-4 with the γ-secretase inhibitor DAPT shows promise in treating HER2-amplified breast cancer.

Authors:  Feng Su; Shilin Zhu; Jinlan Ruan; Yagmur Muftuoglu; Longbo Zhang; Qianying Yuan
Journal:  Oncotarget       Date:  2016-01-26

5.  Circulating-free DNA Mutation Associated with Response of Targeted Therapy in Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer.

Authors:  Qing Ye; Fan Qi; Li Bian; Shao-Hua Zhang; Tao Wang; Ze-Fei Jiang
Journal:  Chin Med J (Engl)       Date:  2017-03-05       Impact factor: 2.628

6.  Sensitization of MCF7 Cells with High Notch1 Activity by Cisplatin and Histone Deacetylase Inhibitors Applied Together.

Authors:  Anna Wawruszak; Jarogniew Luszczki; Marta Halasa; Estera Okon; Sebastian Landor; Cecilia Sahlgren; Adolfo Rivero-Muller; Andrzej Stepulak
Journal:  Int J Mol Sci       Date:  2021-05-13       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.